Sardona Therapeutics is a precision oncology company that is developing a portfolio of small molecules targeting RNA-binding proteins (RBPs) for the treatment of cancer. By targeting RBPs, Sardona’s small molecules are designed to modulate downstream dysregulated RNA that are causative of tumor growth resulting in a differentiated approach to tackle clinically-validated oncogenic drivers for the treatment of cancer.
